Researchers at the Medical College of Georgia have shown in an animal model of retinopathy of prematurity that the small molecule K604 can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth.
Aviceda Therapeutics appoints Patrick Johnson, a strategic pharmaceutical executive, to its board of directors.
Eyetelligence will offer non-invasive point-of-care technology to diagnose a range of diseases, including diabetic retinopathy and age-related macular degeneration, with AI algorithmic retinal image analysis.
A study by Verana Health shows how de-identified real-world data (RWD) from electronic health records (EHRs) in medical registries can allow for a deeper understanding of data trends, patterns, or gaps.
Leo P. Semes, OD, shared his insights on early detection of age-related macular degeneration during the 17th annual Controversies in Modern Eye Care symposium in Los Angeles, California.
This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.
David S. Boyer, MD, senior partner at Retina Vitreous Associates Medical Group, shares key takeaways from "Advances in geographic atrophy," which he co-presented.
Espansione Group announced the second wave of its major research effort for the prevention and management of dry AMD.
If approved, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
The study results show the potential of SREDs to treat progressive, chronic retina conditions including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).
The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy.
Prevent Blindness has declared the week of May 15-21 as Inherited Retinal Disease (IRD) Genetic Testing Week to promote awareness and provide resources to understand the impact of genetic testing and treatment options.
With the newly modified lighted endolaser probe, an 18-gauge angiocatheter sleeve protects against vitreous disturbance.
Researchers compile data from around 18,000 patients to provide a comprehensive understanding of the current state of nAMD treatment in the UK.
Researchers collaborate to study AMD through database of donor eye tissue to provide new data for study and future treatment targeting.
New clinic dedicated to treating pediatric uveitis opens in the UAE.
Researchers in Australia have identified genes that play a role in oxidative stress and aging in the macula.
Roger Goldberg, MD, MBA, spoke with Ophthalmology Times® to share insights about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept.
Endogena Therapeutics Inc. has completed patient enrollment ahead of schedule with a cohort of 14 patients with RP due to any pathologic genetic mutation across 5 US sites.
Michael Ip, MD, highlighted the results of the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.
Allen Chiang, MD, discussed the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials with our team at the 2023 ARVO annual meeting.
Christine Kay, MD, discussed research for the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting held in New Orleans.
Caroline Baumal, MD, spoke with our onsite team at the 2023 ARVO annual meeting to share more about Apellis' presentations focusing on visual function, imaging and artificial intelligence.
Dierck Hillmann, PhD, was interviewed by our onsite team at the 2023 ARVO annual meeting where he shared research on holographic optical coherence tomography (OCT).
Theresa Heath, MD, MBA, spoke with our onsite team at this year's ARVO annual meeting in New Orleans where she shared insights regarding Non-viral gene therapy targeting ABCA4 retinopathies.
FDA has cleared Atsena Therapeutics' Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS).
Kiora Pharmaceuticals presented preliminary results for its investigational drug, KIO-301, a light-sensing small molecule designed to reactivate visual function of the eye in response to light.
Astellas Pharma has agreed to acquire Iveric Bio for a reported $5.9 billion (USD) with the goal of continuing progress in the innovation of ophthalmic therapeutics.
The presentations highlighted the Clearside Biomedical’s efforts in suprachoroidal delivery of agents to the back of the eye.
Kaushal Solanki, PhD, CEO and founder of Eyenuk, shared news about the company's EyeArt AI, which is cleared by the FDA to detect diabetic retinopathy.
